W. Bernard
{"title":"Muscle and Neuromuscular Junction Disorders","authors":"W. Bernard","doi":"10.1201/b15187-14","DOIUrl":"https://doi.org/10.1201/b15187-14","url":null,"abstract":"AAN. See American Academy of Neurology Acetylcholine, 1789, 1978Y1979 Acetylcholine receptor (AChR), 1978Y1979 Acetylcholine receptor (AChR) antibodies in myasthenia gravis, 1979Y1980 babies of mothers with MG, 1981 diagnostic specificity of, 1981, 1988 immunomodulatory treatment and, 1995Y1996 LRP4 antibodies and, 1988 MuSK antibodies and, 1984 myasthenia-myositis overlap, 1865 thymic pathology and, 1981, 1988, 1996 Acetylcholinesterase, 1909, 1914r, 1979, 1992 N-Acetylcysteine, for congenital myopathies, 1940, 1950 AChR. See Acetylcholine receptor Acid maltase deficiency, 1790t, 1893t, 1922, 1968, 1974t, 1975t Acromegaly, 1815, 1816t, 1821, 1826r ACTA1 gene, 1934t, 1937, 1940c, 1942, 1944, 1946, 1950, 1953r !-Actin 1 gene. See ACTA1 gene Acute renal failure, 1833, 1834, 1839, 1866t Acute respiratory distress syndrome, 1822c, 1827r Acylcarnitine profile, 1811 in metabolic myopathies, 1829, 1837, 1839Y1841, 1841c, 1847 Addison disease, 1821 Adenosine diphosphate (ADP), 1804, 1830 Adenosine monophosphate (AMP), 1830 Adenosine triphosphate (ATP), 1804, 1830, 1832, 1845 ADP (adenosine diphosphate), 1804, 1830 Adrenal dysfunction, 1815, 1816t, 1820Y1821 Aerobic exercise intensity, 1831 Agency for Healthcare Research and Quality, 2012 Agency for Toxic Substances and Disease Registry, 2014 Agrin, 1979 Agrin antibodies in myasthenia gravis, 1980, 1981, 1988, 2003r Alanine aminotransferase (ALT) level, 1811 in dermatomyositis, 1792c, 1856 in myasthenia gravis, 1994 Albuterol for core myopathies, 1940, 1952r for facioscapulohumeral muscular dystrophy, 1926, 1931r Alcohol myopathy, 1804t, 1816t, 1826, 1828r Aldolase A deficiency, 1831t, 1833 Alemtuzumab, for inclusion body myositis, 1883, 1885t, 1888r ALS. See Amyotrophic lateral sclerosis ALS Association, 2014 ALT. See Alanine aminotransferase level American Academy of Neurology (AAN) Axoni Registry, 2014, 2014r management guidelines for facioscapulohumeral muscular dystrophy, 1926 Amino acid oxidation defects, 1829 Amiodarone myopathy, 1815, 1816t, 1817t, 1824Y1825, 1827r Ammonia level, in glycogen-storage diseases, 1834c, 1835, 1836, 1837t, 1847 AMP (adenosine monophosphate), 1830 AMPD1 gene, 1835, 1848r Amphiphysin 2 gene. See BIN1 gene Amyloid-\" precursor protein, 1878Y1879, 1887r Amyloid deposition, 1799 in inclusion body myositis, 1878, 1882, 1887r in limb-girdle muscular dystrophy, 1964, 1976t Amyotrophic lateral sclerosis (ALS), 1790t, 2010r EMG in, 1986, 1987 vs. inclusion body myositis, 1872, 1879 LRP4 antibodies in, 1988 vs. myasthenia gravis, 1986, 1987, 1990t national registry for, 014r, 2014 VCP-related, 2007, 2008, 2010r Anaerobic threshold, 1831 Angiotensin-converting enzyme inhibitors in dystrophinopathies, 1971 in McArdle disease, 1839 ANO5 gene, 1829, 1848r, 1961t, 1966 Anoctaminopathy (LGMD type 2L), 1961t, 1966, 1974t, 1975t Antidepressants in dystrophinopathies, 1973 in facioscapulohumeral muscular dystrophy, 1927 tricyclic in myotonic dystrophy, 1904, 1907t in nondystrophic myotonia","PeriodicalId":129531,"journal":{"name":"Equine Pediatric Medicine","volume":"145 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130278789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：